IBSA FARMACEUTICI ITALIA SRL
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.ibsa.it
Clinical Trials
11
Active:0
Completed:6
Trial Phases
1 Phases
Not Applicable:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Not Applicable
10 (100.0%)Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
Not Applicable
Recruiting
- Conditions
- Facial DrynessFacial Dullness
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- IBSA Farmaceutici Italia Srl
- Target Recruit Count
- 500
- Registration Number
- NCT06914583
- Locations
- 🇨🇳
Peking Union Medical College Hospital (PUMCH), Beijing, China
🇨🇳Peking University First Hospital, Beijing, China
🇨🇳The First Principle Hospital of Changde City, Changde, China
Evaluation of the Effects of Two Dietary Supplement Formulations on the Lipid Profile in Mild Hypercholesterolemia
Not Applicable
Recruiting
- Conditions
- Hypercholesterolemia and HyperlipidemiaSupplementation
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- IBSA Farmaceutici Italia Srl
- Target Recruit Count
- 99
- Registration Number
- NCT06810466
- Locations
- 🇮🇹
S. Orsola-Malpighi University Hospital, Bologna, Italy
Evaluation of the Safety and Efficacy of Profhilo® Structura
Recruiting
- Conditions
- Skin Aging
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- IBSA Farmaceutici Italia Srl
- Target Recruit Count
- 164
- Registration Number
- NCT06719154
- Locations
- 🇫🇷
Eurofins Dermscan Pharmascan, Villeurbanne, Lyon, France
🇵🇱Eurofins Dermscan Poland, Gdansk, Poland
🇵🇱Aesthetic clinical, Poznan, Poland
Assessment of the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.
Not Applicable
Completed
- Conditions
- Helicobacter Pylori Infection
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- IBSA Farmaceutici Italia Srl
- Target Recruit Count
- 270
- Registration Number
- NCT06499649
- Locations
- 🇮🇹
Policlinico S. Orsola - Malpighi - Università di Bologna, Bologna, Italy
Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters
Not Applicable
Recruiting
- Conditions
- Weight Loss
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- IBSA Farmaceutici Italia Srl
- Target Recruit Count
- 60
- Registration Number
- NCT06193577
- Locations
- 🇮🇹
A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy
- Prev
- 1
- 2
- 3
- Next
News
No news found